araag2/HINT huggingface dataset:
Clinical trial NCT01264692 (phase 2, status: completed)
Conditions: essential hypertension
ICD codes: I10, O10.02, O10.03, O10.011, O10.012, O10.013, O10.019
Drugs: act-280778, placebo, amlodipine
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females aged 18 to 75 years (inclusive) at screening.

          -  Body mass index (BMI) between 18 and 35 kg/m2 (inclusive) and body weight at least 50
             kg at screening and prior to enrollment.

          -  12-lead ECG without clinically relevant abnormalities measured at screening.

          -  Clinical chemistry, hematology, coagulation, virus serology, and urinalysis test
             results not deviating to a clinically relevant extent from the normal range at
             screening.

          -  Signed informed consent in the local language prior to any study-mandated procedure

        Exclusion Criteria:

          -  Mean SBP > 180 mmHg.

          -  Severe, malignant, or secondary hypertension.

          -  Episodes of hypertensive crisis or hypertensive emergency within 6 months prior to
             enrollment.

          -  Previous history of fainting, collapse, syncope, orthostatic hypotension, or vasovagal
             reactions considered to be of clinical significance.

          -  E6 Severe coronary artery disease indicated by myocardial infarction, percutaneous
             coronary intervention, or coronary artery bypass graft within the last 12 months prior
             to enrollment.

          -  Angina pectoris within 6 months prior to enrollment
Clinical trial NCT00529789 (phase 2, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: duloxetine
SMILES: CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Male / Female outpatients 7 to 17 years of age diagnosed with Major Depressive
             Disorder (MDD). (Must have a Children's Depression Rating Scale-Revised [CDRS-R] with
             a total score greater than or equal to 40 at Visit 1, Visit 2, and Visit 3 and a
             Clinical Global Impressions of Severity [CGI-Severity] rating of greater than or equal
             to 4 at Visit 1, Visit 2, and Visit 3.)

          -  Female patients must test negative on a pregnancy at visit 1.

        Exclusion Criteria:

          -  Have a serious or unstable medical illness, psychological condition, clinically
             significant laboratory or electrocardiogram (ECG) result, hypersensitivity to
             duloxetine, or to its inactive ingredients, frequent or severe allergic reactions to
             multiple medications, uncontrolled narrow-angle glaucoma, acute liver injury (for
             example, hepatitis) or severe cirrhosis (Child-Pugh Class C) that in the opinion of
             the investigator would compromise participation in the study or be likely to lead to
             hospitalization during the course of the study.

          -  Have a current or previous diagnosis of bipolar disorder, psychotic depression,
             schizophrenia or other psychotic disorder, anorexia, bulimia, obsessive compulsive
             disorder, pervasive development disorder or borderline personality disorder, as
             determined by the investigator.

          -  Have a significant suicide attempt within 1 year of Visit 1 or have a score of 5 or
             greater on Item 13 (Suicidal Ideation) on the CDRS-R at Visit 1, Visit 2, or Visit 3,
             or are currently at risk of suicide in the opinion of the investigator.

          -  Have a weight less than 20 kg at any Screening Phase visit.

          -  Have previous exposure to duloxetine

          -  Female patients who are either pregnant, nursing or have recently given birth.
Clinical trial NCT01203943 (phase 2, status: terminated)
Conditions: idiopathic pulmonary fibrosis, pulmonary fibrosis, fibrosis, interstitial lung disease, lung diseases, interstitial
ICD codes: J84.112, J84.10, J84.112, E84.0, J84.178, K74.01, K74.02, E84.9, J84.10, J84.112, K13.5, K74.00, J84.115, J84.170, J84.848, J84.115, J84.170, J84.848
Drugs: cc-930, cc-930, cc-930
SMILES: [H][C@@]1(CCOC1)N1C(NC2=C(F)C=C(F)C=C2F)=NC2=CN=C(N[C@@]3([H])CC[C@]([H])(O)CC3)N=C12, [H][C@@]1(CCOC1)N1C(NC2=C(F)C=C(F)C=C2F)=NC2=CN=C(N[C@@]3([H])CC[C@]([H])(O)CC3)N=C12, [H][C@@]1(CCOC1)N1C(NC2=C(F)C=C(F)C=C2F)=NC2=CN=C(N[C@@]3([H])CC[C@]([H])(O)CC3)N=C12
Reason stopped: 
    the benefit/ risk profile does not support continuation of this study.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females of non-childbearing potential ≥50 years of age (at the time of
             signing the informed consent document) with documented IPF

          -  Diagnosis of IPF based on current ATS/ERS guidelines

               -  Usual interstitial pneumonia (UIP) pattern on HRCT and/or UIP pattern on
                  histopathology (ie surgical lung biopsy), and

               -  Exclusion of known causes of interstitial lung disease (such as environmental
                  exposure, connective tissue disease and drug toxicity), Or

               -  UIP pattern on surgical lung biopsy required if HRCT is inconsistent with UIP

        Exclusion Criteria:

          -  FVC : < 50% predicted >90% predicted

          -  DLco:< 25% predicted >90% predicted

          -  Saturated oxygen (SpO2) of <92% (room air [sea level] at rest). SpO2 of < 88% (room
             air [≥ 5,000 feet above sea level (1524 meters]) at rest)

          -  Use of any cytotoxic/immunosuppressive agent (other than prednisone ≤ 12.5 mg/day or
             equivalent) including, but not limited to, azathioprine, cyclophosphamide,
             methotrexate and cyclosporine within 4 weeks of screening

          -  Use of any cytokine modulators:

               -  Use of any biologic agent (such as etanercept, adalimumab, efalizumab,
                  infliximab, golimumab, certolizumab) within 12 weeks or five half-lives of
                  screening, and in the case of rituximab, use within 24 weeks of screening or no
                  recovery of CD 19-positive B lymphocytes if the last dose of rituximab has been
                  more than 24 weeks prior to screening

               -  Alefacept within 24 months of randomization

          -  Use of any therapy targeted to treat IPF (including but not limited to
             d-penicillamine, endothelium receptor antagonist [eg bosentan, ambrisentan],
             interferon gamma-1B, pirfenidone) within 4 weeks of screening

          -  Use of n-acetylcysteine (NAC) for IPF (≥1800 mg/day) within 4 weeks of screening

          -  Use of any investigational drug within one month of screening, or 5 PD/PK half lives,
             if known (whichever is longer)

          -  Current smoker
Clinical trial NCT00559910 (phase 2, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: ph-797804, placebo
SMILES: CNC(=O)C1=CC=C(C)C(=C1)N1C(C)=CC(OCC2=C(F)C=C(F)C=C2)=C(Br)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subjects between, and including, the ages of 40 and 80 years.

          -  Subjects with a diagnosis, for at least 6 months, of moderate to severe COPD (GOLD)
             and who meet the criteria for Stage II-III disease, subjects must have had stable
             disease for at least 1 month prior to screening.

          -  Subjects must have a smoking history of at least 10 pack-years and be current smokers
             or ex-smokers that gave up > 6 months ago.

        Exclusion Criteria:

          -  More than 2 exacerbations of COPD requiring treatment with oral steroids in the
             preceding year or hospitalization for the treatment of COPD within 3 months of
             screening or more than twice during the preceding year.

          -  History or presence of significant cardiovascular disease.

          -  ECG abnormalities.

          -  Significant concomitant clinical disease that could interfere with the conduct, safety
             or interpretation of results of this study.

          -  Evidence of organ or blood disorders.
Clinical trial NCT00485394 (phase 2, status: unknown status)
Conditions: age-related macular degeneration
ICD codes: H35.3130, H35.3230, H35.3110, H35.3120, H35.3131, H35.3132, H35.3190
Drugs: ot-551, ot-551, vehicle placebo
SMILES: CC1(C)CC(CC(C)(C)N1O)OC(=O)C1CC1, CC1(C)CC(CC(C)(C)N1O)OC(=O)C1CC1, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  have a clinical diagnosis of GA in one or both eyes;

          -  be of non-childbearing potential

        Exclusion Criteria:

          -  have GA secondary to any condition other than AMD in the study eye;

          -  have a BCVA of 20/200 or worse in the non-study eye;

          -  have a history of or current choroidal neovascularization in either eye, or the need
             for any study eye anti-angiogenic therapy;

          -  have any ocular condition in the study eye that would progress during the course of
             the study and could affect central vision or other ocular conditions that may be a
             confounding factor in this study;

          -  need to wear contact lenses in the study eye during the study;

          -  had confounding ocular surgery in the study eye;

          -  have concomitant treatment with any systemic or ocular medication that is known to be
             toxic to the lens, retina, or optic nerve;
Clinical trial NCT00295776 (phase 2/phase 3, status: terminated)
Conditions: neuralgia, postherpetic
ICD codes: B02.22
Drugs: lamictal in the treatment of post-herpetic neuralgia
SMILES: NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1
Reason stopped: 
    enrollment difficult due to inclusion/exclusion criteria/protocol requirements
  
Eligibility criteria:

        Inclusion Criteria:

          -  All patients will be over the age of 18,

          -  Need to have a diagnosis of Post-Herpetic Neuralgia,

          -  Minimum of 4 on the Likert Pain Scale,

          -  If currently taking TCA and/or Gabapentin, need to have been on stable dose for
             minimum of 4 weeks

        Exclusion Criteria:

          -  Currently on any antiepileptic drugs (AED), except for Gabapentin.

          -  Currently taking opioid or unwilling to washout prior to the study,

          -  Pregnant and lactating,

          -  Have active severe systemic disease,

          -  History of Stevens-Johnson syndrome or TEN,

          -  Clinically significant abnormal lab values,

          -  Known drug allergy to Lamictal,

          -  Patients on Fibrates (Tricor and Lopid),

          -  History of major psychiatric disturbance and substance abuse.

          -  Valproate due to increase chances of severe rash,

          -  Lidocaine Patch,

          -  Use of hormonal contraceptives (birth control pills, patch, ring, injection)
Clinical trial NCT00382239 (phase 2, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: exenatide (ly2148568), exenatide (ly2148568), exenatide (ly2148568), placebo
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, N[C@@H](CCCNC(N)=N)C(O)=O, N[C@@H](CCCNC(N)=N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed with type 2 diabetes.

          -  Have a body weight of >=50 kg.

        Exclusion Criteria:

          -  Have received treatment within the last 30 days with a drug that has not received
             regulatory approval for any indication at the time of study entry.

          -  Have participated in this study previously, or any other study using exenatide or
             other GLP-1 analogs.

          -  Are treated with any exogenous insulin within 3 months of screening.

          -  Are continuously treated with any of the following excluded medications within 3
             months of screening (more than 7 days per 1 month): *drugs that directly affect
             gastrointestinal motility, including Nauzelin® (domperidone), Primperan®/Terperan®
             (metoclopramide), Ganaton® (itopride), Acenalin® (cisapride), Gasmotin® (mosapride),
             or Cerekinon® (trimebutine).

          -  Have characteristics contraindicating for concomitant medication, according to
             product-specific label.

          -  Have severe allergy or hypersensitivity to any drug.
Clinical trial NCT00515086 (phase 2, status: terminated)
Conditions: glioblastoma multiforme
ICD codes: L51.0, L51.8, L51.9
Drugs: everolimus
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Reason stopped: 
    early termination due to slow enrollment and protocol-defined stopping rule.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Age 18 years of age or older

          -  Histologically confirmed Glioblastoma Multiforme (GBM)

          -  Radiographic evidence of disease progression

          -  Patients must have evaluable contrast enhancing tumor

          -  Availability of paraffin blocks or unstained pathology slides for biomarker studies

          -  Karnofsky Performance Status of greater than or equal to 60%

        Exclusion Criteria:

          -  Prior treatment with Mammalian target of rapamycin (mTOR) inhibitor

          -  History of another malignancy within 3 years

          -  Cardiac pacemaker

          -  Ferromagnetic metal implants other than those approves as safe for use in Magnetic
             resonance imaging (MRI) scanners

          -  Claustrophobia

          -  Obesity

          -  Unstable systemic diseases

          -  Elevated cholesterol or triglycerides

          -  Radiation therapy or cytotoxic chemotherapy <=4 weeks prior to study enrollment.
             Patient must have recovered from the toxic effects of a prior chemotherapy.

          -  Patients must be off all enzyme inducing anticonvulsants for at least 2 week before
             study enrollment can occur

          -  Need for increasing dose of steroids. Patients on a stable or tapering dose of
             steroids >=7 days were permitted.
Clinical trial NCT00257426 (phase 2, status: completed)
Conditions: liver cancer
ICD codes: D13.4, Z85.05, C22.8, C78.7, C22.9, D37.6
Drugs: octreotide acetate
SMILES: [H][C@]1(NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@H](CO)[C@@H](C)O)NC(=O)[C@H](N)CC1=CC=CC=C1)[C@@H](C)O
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Newly diagnosed or recurrent hepatocellular carcinoma (HCC) as defined by tissue
             biopsy OR alpha fetoprotein (AFP) > 1,000 ng/mL with compatible mass on CT scan or MRI

               -  Recurrence of previously resected HCC will not require tissue confirmation if
                  there is clear radiographic recurrence, in the judgment of the investigator

          -  Locally advanced OR metastatic disease

          -  Unmeasurable disease allowed if initial diagnosis was made according to the above
             criteria and/or recurrence has been confirmed by tissue biopsy or radiological imaging

          -  CLIP score ≥ 3

          -  Not a candidate for surgical resection or liver transplant

          -  Not a candidate for loco-regional therapy (e.g., ablation, embolization, hepatic
             arterial infusion therapy), but could have received such therapy in the past

          -  No fibrolamellar HCC

          -  No clinically apparent central nervous system metastases or carcinomatous meningitis

        PATIENT CHARACTERISTICS:

          -  Life expectancy ≥ 8 weeks

          -  Karnofsky performance status 60-100%

          -  Hemoglobin ≥ 8.5 g/dL

          -  Platelet count ≥ 50,000/mm³

          -  Total bilirubin ≤ 5.0 mg/dL

          -  AST or ALT ≤ 5 times upper limit of normal (ULN)

          -  Creatinine ≤ 2 times ULN

          -  PT ≤ 28

          -  INR ≤ 2.5

          -  No active variceal bleeding within the past 3 months

          -  No encephalopathy grade 3-4

          -  No ongoing ethanol or intravenous drug abuse

          -  Not pregnant or breast feeding

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  Any number of prior therapies (e.g., chemotherapy, resection, embolization, or
             radiofrequency/ethanol ablation therapy) allowed

          -  No concurrent chemotherapy, radiotherapy, or immunotherapy
Clinical trial NCT01423032 (phase 2/phase 3, status: completed)
Conditions: chronic lymphocytic leukemia
ICD codes: C91.11, C91.12, C91.10
Drugs: bendamustine, fludarabine
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          -  histologically or immunologically confirmed chronic B-cell leukemia

          -  refractory (i.e. no response or progression during initial chemotherapy) or relapsed
             situation after first-line treatment regimen

          -  disease stage II-IV according to Rai or B/C according to Binet staging system,
             respectively

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 3 or better

          -  negative pregnancy test/ adequate method of contraception

        Exclusion Criteria:

          -  T-CLL, PLL (prolymphocytic leukemia)

          -  presence of Richter's transformation

          -  first-line treatment containing either fludarabine or bendamustine

          -  acute infections or distinctly reduced organ function precluding the application of
             chemotherapy, as for pulmonary, heart, liver (total bilirubin > 5mg/dl), renal system
             (creatinine > 2 mg/dl), or metabolic disorders

          -  secondary malignancy (except for curative treated basal cell carcinoma or cervical
             cancer)
Clinical trial NCT00550810 (phase 2, status: unknown status)
Conditions: prostate cancer, hormone refractory
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: sunitinib (su011248)
SMILES: CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
Eligibility criteria:

        Inclusion Criteria:

          -  Histological or cytological diagnosis of adenocarcinoma of the prostate

          -  Metastatic or locally recurrent disease not curable with standard therapy

          -  ECOG performance status 0, 1 or 2

          -  Prior single agent docetaxel or docetaxel combination chemotherapy with a documented
             PSA or imaging response, and no objective evidence of disease progression at study
             enrolment

        Exclusion Criteria:

          -  Patients with a history of other invasive cancer, except adequately treated non

          -  melanoma skin cancer.

          -  Patients with known brain metastases.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to SU011248.

          -  Other serious intercurrent illness or medical condition that might be aggravated by
             protocol treatment.
Clinical trial NCT01336088 (phase 2, status: completed)
Conditions: parkinson's disease
ICD codes: G20
Drugs: adx48621, placebo
SMILES: FC1=CN2C=C(CCC#CC3=CC=CC=N3)N=C2C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  outpatient with idiopathic PD according to the UK Parkinson's Disease Society Brain
             Bank Clinical Diagnosis Criteria (UKPDSBBCDC)

          -  experiences moderately disabling dyskinesia (screening visit UPDRS 33 score≥2)

          -  has an mAIMS score at baseline ≥ 7 with a score ≥ 3 in at least one body area

        Exclusion Criteria:

          -  surgical treatment for Parkinson's disease (e.g. Deep Brain Stimulation, within the
             last year or planned during the study)

          -  unstable co-existing psychiatric disease including cognitive impairment that,
             according to the Investigator, could interfere with the conduct of the study

          -  has a history of a significant medical condition that may affect the safety of the
             patient or preclude adequate participation in the study.

          -  is pregnant or breast-feeding. Female patients who are of child-bearing potential must
             be using adequate contraceptive methods (e.g. oral contraceptive, double-barrier
             method, intra-uterine device, intra-muscular hormonal contraceptive), and have a
             negative pregnancy test at Screening

        Other protocol-defined inclusion and exclusion criteria may apply
Clinical trial NCT02840162 (phase 2, status: terminated)
Conditions: adenocarcinoma of the prostate, prostate cancer
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31, C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: celecoxib, placebo
SMILES: COC1=CC=C(C=C1)C(=O)CC(=O)C1=CC=C(C=C1)C(C)(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    drug safety concerns
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histopathologically or cytologically proven adenocarcinoma of the prostate and planned
             prostatectomy

          -  Age >= 18

          -  Performance status (ECOG <= 2)

          -  Hemoglobin > 10 g/dL (within 4 weeks)

          -  Creatinine <= 1.5 mg/dL

          -  Signed informed patient consent

        Exclusion Criteria:

          -  Other preoperative or prior treatment directed at prostate cancer

          -  Significant active medical illness which in the opinion of the investigator would
             preclude protocol treatment

          -  Use of non-steroidal anti-inflammatory agents within seven days of celecoxib treatment

          -  Hypersensitivity to celecoxib

          -  A history of asthma, urticaria, or anaphylaxis precipitated by an NSAID

          -  History of significant upper gastrointestinal bleeding or active peptic ulcer disease

          -  Current treatment with anticoagulants

          -  Allergy to sulfonamide
Clinical trial NCT00642824 (phase 2, status: terminated)
Conditions: non-squamous non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: standard chemotherapy, bevacizumab [avastin]
SMILES: [Ta], [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    terminated due to low enrollment. no statistical analyses were performed.
  
Eligibility criteria:

        Inclusion Criteria:

          -  participating in, and meeting all inclusion/exclusion criteria of, MO19390.

        Exclusion Criteria:

          -  not meeting the inclusion/exclusion criteria of MO19390.